These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32383189)

  • 61. Relapse of chilblain-like lesions during the second wave of the COVID-19 pandemic: a cohort follow-up.
    Hubiche T; Le Duff F; Fontas E; Rapp J; Chiaverini C; Passeron T
    Br J Dermatol; 2021 Oct; 185(4):858-859. PubMed ID: 34128539
    [No Abstract]   [Full Text] [Related]  

  • 62. Course and outcome of chilblain-like acral lesions during COVID-19 pandemic.
    Blau K; Lehr S; Aschoff R; Al Gburi S; Brück N; Chapsa M; Schnabel A; Abraham S; Jöhrens K; Beissert S; Günther C
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e29-e31. PubMed ID: 36149533
    [No Abstract]   [Full Text] [Related]  

  • 63. Idiopathic perniosis presenting as acral purpuric lesions: Clustering of cases before COVID-19 pandemic and their comparison with chilblain like lesions reported in the literature.
    Jindal R; Chauhan P; Goyal D; Shirazi N
    Dermatol Ther; 2021 May; 34(3):e14951. PubMed ID: 33740317
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relapse of chilblain-like lesions during the second wave of coronavirus disease 19.
    Recalcati S; Barbagallo T; Tonolo S; Milani M; Fantini F
    J Eur Acad Dermatol Venereol; 2021 May; 35(5):e315-e316. PubMed ID: 33586154
    [No Abstract]   [Full Text] [Related]  

  • 65. Chronic chilblain-like lesions occurring during the Covid pandemic: case series.
    Nathan J; Rastogi A; Kiely PDW
    Clin Exp Rheumatol; 2023 Nov; 41(11):2338. PubMed ID: 37279151
    [No Abstract]   [Full Text] [Related]  

  • 66. Long-term Outcome of Chilblains Associated with SARS-CoV-2.
    Poizeau F; Barbarot S; Le Corre Y; Brenaut E; Samimi M; Aubert H; Toubel A; Dupuy A
    Acta Derm Venereol; 2021 Dec; 101(12):adv00614. PubMed ID: 34515805
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pandemic chilblains: Are they SARS-CoV-2-related or not?
    De Greef A; Coulie PG; Baeck M
    Clin Immunol; 2022 Apr; 237():108984. PubMed ID: 35338000
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Perniosis during the COVID-19 pandemic: Negative anti-SARS-CoV-2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS-CoV-2.
    Ko CJ; Harigopal M; Damsky W; Gehlhausen JR; Bosenberg M; Patrignelli R; McNiff JM
    J Cutan Pathol; 2020 Nov; 47(11):997-1002. PubMed ID: 32745281
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oral cinnarizine for the treatment of COVID-19-associated chilblain-like lesions: An old drug for a new disease?
    Mazzatenta C; Piccolo V; Argenziano G; Bassi A
    Dermatol Ther; 2022 May; 35(5):e15365. PubMed ID: 35137498
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Response to Reader Comment Regarding "Approach to Chilblains During the COVID-19 Pandemic".
    Ladha MA; Luca N; Constantinescu C; Naert K; Ramien ML
    J Cutan Med Surg; 2021; 25(3):344-345. PubMed ID: 33624518
    [No Abstract]   [Full Text] [Related]  

  • 71. Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic.
    Moghadam P; Frumholtz L; Jaume L; De Masson A; Jachiet M; Begon E; Sulimovic L; Petit A; Bachelez H; Bagot M; Bouaziz JD; Cassius C;
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e566-e568. PubMed ID: 34036642
    [No Abstract]   [Full Text] [Related]  

  • 72. SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion.
    Gambichler T; Reuther J; Stücker M; Stranzenbach R; Torres-Reyes C; Schlottmann R; Schmidt WE; Hayajneh R; Sriram A; Becker JC
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):e187-e189. PubMed ID: 33002210
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chilblain-like lesions and COVID-19: second wave, second outbreak.
    Piccolo V; Bassi A; Russo T; Mazzatenta C; Baraldi M; Argenziano G; Neri I; Cutrone M
    J Eur Acad Dermatol Venereol; 2021 May; 35(5):e316-e318. PubMed ID: 33545745
    [No Abstract]   [Full Text] [Related]  

  • 74. COVID toes or pernio?
    Zaladonis A; Huang S; Hsu S
    Clin Dermatol; 2020; 38(6):764-767. PubMed ID: 33341212
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Focus on "COVID Toes".
    Hernandez C; Bruckner AL
    JAMA Dermatol; 2020 Sep; 156(9):1003. PubMed ID: 32584385
    [No Abstract]   [Full Text] [Related]  

  • 76. A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2?
    Lipsker D
    Med Hypotheses; 2020 Nov; 144():109959. PubMed ID: 32534339
    [No Abstract]   [Full Text] [Related]  

  • 77. Emerging Evidence of the Direct Association Between COVID-19 and Chilblains.
    Freeman EE; McMahon DE; Fox LP
    JAMA Dermatol; 2021 Feb; 157(2):238-239. PubMed ID: 33355601
    [No Abstract]   [Full Text] [Related]  

  • 78. Erythematous-edematous type of chilblain-like lesions and COVID-19: An Indian perspective.
    Das A; Singh V
    Dermatol Ther; 2020 Nov; 33(6):e13912. PubMed ID: 32594608
    [No Abstract]   [Full Text] [Related]  

  • 79. Immunoglobulin A Antiphospholipid Antibodies in Patients With Chilblain-like Lesions During the COVID-19 Pandemic.
    Cuenca Saez MA; Gomez-Biezna SL
    Actas Dermosifiliogr (Engl Ed); 2021 Mar; 112(3):290-292. PubMed ID: 32905788
    [No Abstract]   [Full Text] [Related]  

  • 80. SARS-CoV-2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions.
    Brealey JK; Miller SE
    Br J Dermatol; 2021 Jan; 184(1):186. PubMed ID: 33000462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.